Silence Therapeutics
SLN
56 hedge funds and large institutions have $102M invested in Silence Therapeutics in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 6 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
3.85% more ownership
Funds ownership: 38.3% → 42.15% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
4% less capital invested
Capital invested by funds: $106M → $102M (-$3.99M)
3% less funds holding
Funds holding: 58 → 56 (-2)
48% less call options, than puts
Call options by funds: $100K | Put options by funds: $192K
Top Buyers
Top Sellers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.72M |
| 2 |
Morgan Stanley
New York
|
-$1.43M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.15M |
| 4 |
II
Ishara Investments
Los Angeles,
California
|
-$548K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$480K |
SLN Hedge Fund Activity: Q1 2026 in Review
56 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2026, worth a combined $102M — down 3.8% from $106M a quarter earlier.
Fund positioning in SLN was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 24 added to existing stakes and 11 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $5.45M. The largest seller was Vivo Capital, exiting entirely with an estimated $6.72M sold.
- 56 institutional investors held Silence Therapeutics (SLN) as of Q1 2026, down from 58 in Q4 2025.
- Funds reported $102M of Silence Therapeutics stock for Q1 2026, down 3.8% quarter-over-quarter.
- 6 funds opened new Silence Therapeutics positions in Q1 2026 and 6 closed out, a net change of 0 holders.
- The largest Silence Therapeutics buyer in Q1 2026 was Citadel Advisors, an estimated $5.45M added.
- The largest Silence Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $6.72M sold.
Based on aggregated 13F filings for Q1 2026.